Related references
Note: Only part of the references are listed.Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy
Katie L. Lentz et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2020)
Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy
Eyad Z. Gharaibeh et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database
Misa Naganuma et al.
SAGE OPEN MEDICINE (2018)
Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database
Shiori Hasegawa et al.
PLOS ONE (2017)
Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database
Junko Abe et al.
PLOS ONE (2017)
Influence of Japanese Regulatory Action on Denosumab-Related Hypocalcemia Using Japanese Adverse Drug Event Report Database
Mayu Takeyama et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2017)
Ifosfamide-induced Encephalopathy Precipitated by Aprepitant: A Rarely Manifested Side Effect of Drug Interaction
Pritam Sureshchandra Kataria et al.
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2017)
Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients
Natacha Stern et al.
BULLETIN DU CANCER (2017)
Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis
Yin Lo et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2016)
On determining the most appropriate test cut-off value: the case of tests with continuous results
Farrokh Habibzadeh et al.
BIOCHEMIA MEDICA (2016)
Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database
Yukiya Suzuki et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases
Kaori Nomura et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center
Audrea H. Szabatura et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2015)
Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events
Mitsuhiro Nakamura et al.
JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES (2015)
Illustration of the Weibull Shape Parameter Signal Detection Tool Using Electronic Healthcare Record Data
Odile Sauzet et al.
DRUG SAFETY (2013)
Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors
Takahiro Tajino et al.
JOURNAL OF ORTHOPAEDIC SCIENCE (2010)
Successful treatment of ifosfamide neurotoxicity with dexmedetomidine
Philip A Bernard et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2010)
Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity
Ashley Richards et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2010)
Central and peripheral nervous system toxicity of common chemotherapeutic agents
Chrissa Sioka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Quantitative signal detection using spontaneous ADR reporting
A. Bate et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect
Mara A. McAdams et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2008)
Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant
Joshua E Howell et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2008)
Evaluating risk factors for the development of ifosfamide encephalopathy
KA David et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2005)
Incidence and severity of ifosfamide-induced encephalopathy
C Rieger et al.
ANTI-CANCER DRUGS (2004)
Replication of the weber effect using postmarketing adverse event reports voluntarily submitted to the United States food and drug administration
NR Hartnell et al.
PHARMACOTHERAPY (2004)
Share Paper
